Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MapLight Therapeutics, Inc.MPLT · Entity 5316 | Director | April 15, 2026 | April 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MapLight Therapeutics, Inc.
Report date April 15, 2026 · Filed April 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | Direct | 316,466 |
Reported balance
After 2026-04-15 transaction · row 1
1 source rowRow 1 · 2026-04-15 · Sale · Disposed 8,593 · Balance 316,466 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.35 to $27.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnote | 31,672 |
Reported balance
Holding disclosure · report date 2026-04-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 31,672 F3: The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.
F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.35 to $27.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 8,593 | $26.90 | $231,151.70 |
DisclosureSEC source: 0002021198-26-000013 · form4-04172026_040402.xml · nonDerivative · entry 1 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,466 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.35 to $27.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2026 Filed Feb 24, 2026 23:57 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 736 | $18.15 | $13,358.40 |
DisclosureSEC source: 0002021198-26-000011 · form4-02242026_110209.xml · nonDerivative · entry 4 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,059 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.01 to $18.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 23:57 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 476 | $19.06 | $9,072.56 |
DisclosureSEC source: 0002021198-26-000011 · form4-02242026_110209.xml · nonDerivative · entry 3 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,795 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 23:57 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 10,788 | $18.39 | $198,391.32 |
DisclosureSEC source: 0002021198-26-000011 · form4-02242026_110209.xml · nonDerivative · entry 2 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,271 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:57 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 2,195 | $18.03 | $39,575.85 |
DisclosureSEC source: 0002021198-26-000011 · form4-02242026_110209.xml · nonDerivative · entry 1 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,059 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 00:33 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 12,116 | $18.21 | $220,632.36 |
DisclosureSEC source: 0002021198-26-000009 · form4-02192026_120233.xml · nonDerivative · entry 1 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,254 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 22:45 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 241 | $18.00 | $4,338.00 |
DisclosureSEC source: 0002021198-26-000007 · form4-02122026_050201.xml · nonDerivative · entry 2 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,370 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 22:45 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 6,622 | $18.12 | $119,990.64 |
DisclosureSEC source: 0002021198-26-000007 · form4-02122026_050201.xml · nonDerivative · entry 1 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,611 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 02:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 1 | $18.00 | $18.00 |
DisclosureSEC source: 0002021198-26-000005 · form4-02052026_020204.xml · nonDerivative · entry 2 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,233 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 7,039 | $18.02 | $126,842.78 |
DisclosureSEC source: 0002021198-26-000005 · form4-02052026_020204.xml · nonDerivative · entry 1 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,234 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 30, 2026 Filed Jan 31, 2026 01:50 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 6,612 | $18.11 | $119,743.32 |
DisclosureSEC source: 0002021198-26-000003 · form4-01312026_010139.xml · nonDerivative · entry 4 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,273 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 29, 2026 Filed Jan 31, 2026 01:50 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 21,262 | $18.55 | $394,410.10 |
DisclosureSEC source: 0002021198-26-000003 · form4-01312026_010139.xml · nonDerivative · entry 3 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,885 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.13 to $19.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 01:50 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 664 | $19.05 | $12,649.20 |
DisclosureSEC source: 0002021198-26-000003 · form4-01312026_010139.xml · nonDerivative · entry 2 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,147 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.02 to $19.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 01:50 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 5,860 | $18.61 | $109,054.60 |
DisclosureSEC source: 0002021198-26-000003 · form4-01312026_010139.xml · nonDerivative · entry 1 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,811 F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.01 to $19.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | ConversionSeries C Preferred Stock · Derivative | 65,477 | $0.00 | $0.00 |
DisclosureSEC source: 0002021198-25-000006 · form4-10282025_041005.xml · derivative · entry 4 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Voting Common Stock · 3,895 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F3 · derivative.exercise_date: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F3 · derivative.expiration_date: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F4 · ownership.nature: The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | ConversionVoting Common Stock | 3,895 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002021198-25-000006 · form4-10282025_041005.xml · nonDerivative · entry 2 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 31,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F4 · ownership.nature: The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantEmployee Stock Option (right to buy) · Derivative | 139,610 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0002021198-25-000006 · form4-10282025_041005.xml · derivative · entry 3 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,610 Underlying: Voting Common Stock · 139,610 shares Expires 2035-10-26 F5 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on October 1, 2026, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 34,390 | $0.00 | $0.00 |
DisclosureSEC source: 0002021198-25-000006 · form4-10282025_041005.xml · nonDerivative · entry 1 Malenka Robert C. · CIK 0002021198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 399,671 F1 · shares: Represents a restricted stock unit ("RSU") award. 25% of the RSUs shall vest on October 1, 2026, and 1/16th of the RSUs shall vest on each subsequent January 1, April 1, July 1 and October 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.